Biosimilars applications under review by EMA – January 2021

Biosimilars/General | Posted 15/01/2021 post-comment0 Post your comment

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of biosimilars is based on an abbreviated registration process, which allows biosimilars manufacturers to provide a reduced package of information compared to originator drugs, provided they can prove ‘similarity’ to the originator or reference drug.

EMA logo 1 V13C15

All medicines for human and animal use derived from biotechnology and other high-tech processes (including biosimilars) must be approved via the centralized EMA procedure. EMA has both general and product specific guidelines giving information on the requirements for biosimilar applications submitted to EMA [1].

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP) released on 7 January 2021, the agency is reviewing 12 biosimilar applications. One application is for diabetes treatment insulin human (rDNA). There are currently no biosimilars for insulin human rDNA approved in Europe [2].

The other applications are one for arthritis treatment adalimumab, five for anticancer treatment bevacizumab, one for neutropenia (a lack of white blood cells) treatment in cancer patients pegfilgrastim, one for vision-loss treatment ranibizumab, two for osteoporosis treatment teriparatide and one for breast and gastric-cancer treatment trastuzumab, for which there are already biosimilars available on the European market [2], see Table 1.

Table 1: Biosimilars under review by EMA*
Common name Therapeutic area Number of applications EMA-approved originator(s) Originator company(ies)
Adalimumab Immunosuppressant 1 Humira AbbVie
Bevacizumab Antineoplastic medicines (anticancer) 5 Avastin Roche
Insulin human (rDNA) Diabetes 1 Actrapid/ Humulin Novo Nordisk/Eli Lilly
Pegfilgrastim Immunostimulant (neutropenia) 1 Neulasta Amgen
Ranibizumab Ophthalmological (wet AMD) 1 Lucentis Novartis
Teriparatide Calcium homeostasis (osteoporosis) 2 Forsteo Eli Lilly
Trastuzumab Antineoplastic medicines (anticancer) 1 Herceptin Roche
Total   12    

*Data collected on 15 January 2021.

AMD: age-related macular degeneration; rDNA: recombinant deoxyribonucleic acid.

Source: EMA.

In June 2020, the bevacizumab biosimilar Aybintio (SB8) and the teriparatide biosimilars Livogiva and Qutavina received positive recommendations from EMA’s CHMP [3]. This was followed by European Commission (EC) approval for Aybintio and Livogiva in August 2020 [2].

In July 2020, the bevacizumab biosimilar Equidacent gained EC approval [4].

Then, in December 2020, EMA’s CHMP recommended approval of the bevacizumab biosimilar Onbevzi [5], insulin aspart biosimilar Kixelle [6] and adalimumab biosimilar Yuflyma [7].

Related articles
Generics applications under review by EMA – January 2021

Biosimilars applications under review by EMA – July 2020 

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

References
1. GaBI Online - Generics and Biosimilars Initiative. EU guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-biosimilars 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe  
3. GaBI Online - Generics and Biosimilars Initiative. EMA approves bevacizumab and teriparatide biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/News/EMA-approves-bevacizumab-and-teriparatide-biosimilars 
4. GaBI Online - Generics and Biosimilars Initiative. EC approval for bevacizumab biosimilar Equidacent [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/News/EC-approval-for-bevacizumab-biosimilar-Equidacent 
5. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of bevacizumab biosimilar Onbevzi [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/News/EMA-recommends-approval-of-bevacizumab-biosimilar-Onbevzi 
6. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of insulin aspart biosimilar Kixelle [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/News/EMA-recommends-approval-of-insulin-aspart-biosimilar-Kixelle 
7. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of insulin aspart biosimilar Yuflyma [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jan 15]. Available from: www.gabionline.net/Biosimilars/News/EMA-recommends-approval-of-adalimumab-biosimilar-Yuflyma 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: EMA

comment icon Comments (0)
Post your comment
Related content
Off-patent biologicals/Biomimics approved in Bolivia
AGEMED V21I17MN
Biosimilars/General Posted 17/09/2021
Glosario de términos principales
20 AA010933
Biosimilars/General Posted 10/09/2021
Interactive map for interchangeable biosimilars
US map V18D13
Biosimilars/General Posted 10/09/2021
Biosimilars approved in Costa Rica
MinSalud Costa Rica V21I03
Biosimilars/General Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010